Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4n222 | IM |
administration of Priorix via intramuscular route in a 61 year old; administration of Priorix via intramuscular route; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 61-year-old female patient who received MMR (Priorix) (batch number 4n222, expiry date 13-SEP-2026) for prophylaxis. On 02-MAY-2025, the patient received the 1st dose of Priorix (intramuscular). On 02-MAY-2025, an unknown time after receiving Priorix, the patient experienced inappropriate age at vaccine administration (Verbatim: administration of Priorix via intramuscular route in a 61 year old) and subcutaneous injection formulation administered by other route (Verbatim: administration of Priorix via intramuscular route). The outcome of the inappropriate age at vaccine administration and subcutaneous injection formulation administered by other route were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-MAY-2025 The pharmacist contacted GlaxoSmithKline to request information about the administration of Priorix via intramuscular route in a 61 year old patient, which led to the inappropriate age at vaccine administration and subcutaneous injection formulation administered by other route. The Vaccine Administration Facility is the same as Primary Reporter.